Shares of Jaguar Health Inc (NASDAQ:JAGX) have earned an average broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and one has issued a strong buy rating on the company.
Analysts have set a 12-month consensus price objective of $69.93 for the company and are expecting that the company will post ($7.40) EPS for the current quarter, according to Zacks. Zacks has also assigned Jaguar Health an industry rank of 82 out of 256 based on the ratings given to related companies.
A number of research analysts have issued reports on the stock. ValuEngine lowered shares of Jaguar Health from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Zacks Investment Research lowered shares of Jaguar Health from a “hold” rating to a “sell” rating in a report on Saturday. Finally, HC Wainwright restated a “buy” rating on shares of Jaguar Health in a report on Monday, April 15th.
NASDAQ:JAGX traded down $0.70 on Friday, reaching $6.20. The stock had a trading volume of 374,417 shares, compared to its average volume of 613,196. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.18 and a current ratio of 0.30. Jaguar Health has a 12-month low of $6.07 and a 12-month high of $175.00.
Jaguar Health Company Profile
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Featured Story: Stop Order Uses For Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.